As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained ...
Novartis will construct an active pharmaceutical ingredient (API) facility in Morrisville, North Carolina, the company said ...
The European Medicines Agency (EMA) has launched an advisory group designed to help boost “vaccine confidence” amid growing ...
The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s ...
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos ...
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at ...
Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in the past year as the businesses have ...
As Ekterly nears the one-year anniversary of its FDA approval, Italy’s Chiesi Group is making moves to acquire the rare ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
As regulatory delays continue to plague Regeneron’s efforts to develop Eylea, sales for the eye disease medicine remain in ...
In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results